PSA and blood test diagnostics of prostate cancer
Seikkula, H.; Pettersson, K.; Boström, P.J.
Duodecim; Laaketieteellinen Aikakauskirja 131(17): 1547-1552
2015
ISSN/ISBN: 0012-7183 PMID: 26548101 Document Number: 684500
Gleason grading of tumor biopses is the only method to distinguish clinically significant prostate cancer. Local cancer is usually symptomless, and men would benefit from functional screening. The aim of improving blood test diagnostics is to find those for whom it is profitable on the basis of blood test to proceed to biopsies. Overdiagnosis would be simultaneously avoided. In blood test diagnostics, established use is made only of the levels of prostate-specific antigen (PSA) and free PSA. New methods for blood test diagnosis are "Prostate Health Index" and the four-kallikrein panel.
Document emailed within 1 workday
Related Documents
Parkes, C.; Wald, N.J.; Murphy, P.; George, L.; Watt, H.C.; Kirby, R.; Knekt, P.; Helzlsouer, K.J.; Tuomilehto, J. 1995: Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer BMJ 311(7016): 1340-1343O'Dell, K.J.; Volk, R.J.; Cass, A.R.; Spann, S.J. 1999: Screening for prostate cancer with the prostate-specific antigen test: are patients making informed decisions? Journal of Family Practice 48(9): 682-688
Protoshhak, V.V.; Andreev, E.A.; Karpushhenko, E.G.; Slepcov, A.V.; Ovchinnikov, D.V.; Alentev, S.A.; Lazutkin, M.V.; Mamaenko, A.V.; Mamaenko, T.V. 2019: Prostate cancer and dogs sense of smell: opportunities of noninvasive diagnostics Urologiia 5: 22-26
Srinualnad, S.; Charoenkraikamol, C.; Toraksa, S.; Uiprasertkul, M.; Amornvesukit, T.; Taweemonkongsap, T.; Udompunturak, S.; Nualyong, C.; Tantiwong, A. 2006: Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day) Journal of the Medical Association of Thailand 89(1): 37-42
Zalesky, M.; Urban, M.; Smerhovský, Z.; Zachoval, R.; Lukes, M.; Heracek, J. 2008: Value of power Doppler sonography with 3D reconstruction in preoperative diagnostics of extraprostatic tumor extension in clinically localized prostate cancer International Journal of Urology: Official Journal of the Japanese Urological Association 15(1): 68-75; Discussion 75
Albani, J.M. 2011: Don't test -- don't treat: the new paradigm for the treatment of prostate cancer? Missouri Medicine 108(6): 409-412
Incorvaia, L.; Badalamenti, G.; Rini, G.; Arcara, C.; Fricano, S.; Sferrazza, C.; Di Trapani, D.; Gebbia, N.; Leto, G. 2007: MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone Anticancer Research 27(3b): 1519-1525
Kast, R.E.; Bjerrum, O.W. 1978: Lymphocyte agglutination blocking test. a pilot study of a new simple in vitro blood test for demonstration of cancer and tissue destruction Ugeskrift for Laeger 140(42): 2572-2575
Romppanen, J.; Haapalainen, T.; Punnonen, K.; Penttilä, I. 2002: Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer Anticancer Research 22(1a): 415-420
Murray, N.P.; Aedo, S.óc.; Reyes, E.; Fuentealba, C.; Jacob, O. 2019: Primary circulating prostate cells, age and prostatic volumen predict the presence of prostate cancer in men with indication of a second prostate biopsy Archivos Espanoles de Urologia 72(1): 16-24
Woods, V.Diane.; Montgomery, S.B.; Herring, R.Patti.; Gardner, R.W.; Stokols, D. 2006: Social ecological predictors of prostate-specific antigen blood test and digital rectal examination in black American men Journal of the National Medical Association 98(4): 492-504
Sun, S.-C.; Zhao, H.; Liu, R.; Wang, B.-L.; Liu, Y.-Q.; Zhao, Y.; Shi, Z.-D. 2017: Expression of long non-coding RNA H19 in prostate cancer and its effect on the proliferation and glycometabolism of human prostate cancer cells Zhonghua Nan Ke Xue 23(2): 120-124
Considine, B.; Petrylak, D.P. 2019: Integrating Novel Targets and Precision Medicine into Prostate Cancer Care-Part 1: the Non-Androgen-Targetable Pathways in Castration-Resistant Prostate Cancer Oncology 33(3): 113-118
Grosclaude, P.; Menegoz, F.; Schaffer, P.; Macé Lesec'h, J.; Arveux, P.; Le Mab, G.; Soulié, M.; Villers, A. 1997: Prostate cancer screening (II): is prostate cancer a public health problem? Update of incidence and mortality figures in France from 1982 to 1990 Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 7(4): 647-654
Karamanolakis, D.; Lambou, T.; Bogdanos, J.; Milathianakis, C.; Sourla, A.; Lembessis, P.; Halapas, A.; Pissimissis, N.; Dessypris, N.; Petridou, E.T.; Koutsilieris, M. 2006: Serum testosterone: a potentially adjunct screening test for the assessment of the risk of prostate cancer among men with modestly elevated PSA values (> or =3.0 and <10.0 ng/ml) Anticancer Research 26(4b): 3159-3166
Liu, J-he.; Li, H-wei.; Tong, M.; Li, M.; Na, Y-qun. 2004: Genetic risk factors of prostate cancer in Han nationality population in Northern China and a preliminary study of the reason of racial difference in prevalence of prostate cancer Zhonghua Yi Xue Za Zhi 84(5): 364-368
Ragde, H.; Grado, G.L.; Nadir, B.S. 2001: Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone Archivos Espanoles de Urologia 54(7): 739-747
Fourcade, R-Olivier.; Richaud, P.; Coloby, P.; Malavaud, B. 2007: Role of 150 mg bicalutamide in the treatment of prostate cancer: 3rd analysis of the EPC (early prostate cancer) program Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 17(4 Suppl. 1): 891-910
Perrin, P.; François, O.; Maquet, J.H.; Bringeon, G.; Duteil, P.; Devonec, M. 1991: Circulating prostate cancer specific antigens in benign hypertrophy and localized cancer of the prostate Presse Medicale 20(28): 1313-1319
Liu, B.-q.; Wu, Y.-d.; Wei, J.-x.; Zhang, T.; Liu, R.-l.; Ma, T.-x. 2007: Expression of prostate cancer antigen-1 in prostate cancer and its clinical significance Zhonghua Nan Ke Xue 13(11): 997-1001